ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals has announced a placement of 33,150,000 new H shares at HK$7.05 per share, representing about 8.86% of its issued share capital. This strategic move is set to raise approximately HK$229.73 million in net proceeds, enhancing the company’s financial capabilities. The placement, which requires no shareholder approval, will be conducted under the General Mandate granted earlier this year.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.